ArticleAdvances in radiation oncology2026
Multimodal Nuclear Imaging Response as a Prognostic Indicator Following Spine Stereotactic Body Radiation Therapy.
Article in Advances in radiation oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
17 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Purpose: Magnetic resonance imaging (MRI) is the primary modality for diagnosing and monitoring spinal metastases, but its interpretation can be complicated by nontumor-related changes like fibrosis or osteoradionecrosis. Nuclear imaging can complement MRI in evaluating treatment response. Yet, the prognostic significance of nuclear metabolic response after spine stereotactic body radiation therapy (SBRT) remains underexplored. This study evaluates the utility of nuclear imaging in assessing post-SBRT treatment response and its association with local control (LC) and survival outcomes. Methods and Materials: This retrospective study evaluated spine metastases treated with SBRT focusing on pre- and first available posttreatment positron emission tomography (PET) or bone scans to assess nuclear metabolic response. PET responses were categorized as complete response (CR), partial response, stable disease, or disease progression, while bone scan interpretations were based on nuclear medicine reports. MRI was used for LC assessment. Predictors of LC and overall survival (OS) were identified via Cox regression analyses. Additionally, metabolic responses within the first 3 months and between 4 and 6 months post-SBRT were correlated with 2-year outcomes. Results: Of the 53 patients, 66% underwent PET imaging and 34% underwent bone scans. Nuclear imaging revealed a metabolic CR in 74%, partial response in 13%, stable disease in 5%, and disease progression in 8%. Patients achieving metabolic CR (mCR) had significantly better 2-year LC (97% vs 60%, Conclusions: Multimodal nuclear imaging could provide a valuable functional insight in evaluating response after spine SBRT and may help overcome limitations of MRI. A metabolic CR is a strong independent predictor of LC and survival. Prospective studies with standardized imaging protocols are warranted to guide adaptive treatment strategies.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.